BRIAN DRUKER

M.D., CO-INVENTOR, GLEEVEC

Brian Druker M.D., Director of the Oregon Health & Science University (OHSU) Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, OHSU, and an Investigator of the Howard Hughes Medical Institute. After having trained in oncology at Harvard’s Dana-Farber Cancer Institute, Dr. Druker then returned to the lab to begin his research career studying the regulation of the growth of cancer cells and the practical application to cancer therapies. His work was instrumental in the development of Gleevec, a drug that targets the molecular defect in chronic myeloid leukemia. After completing a series of preclinical studies, Dr. Druker spearheaded the highly successful clinical trials of imatinib for CML. Imatinib is currently FDA approved for CML and gastrointestinal stromal tumors. His role in the development of imatinib and its application in the clinic have resulted in numerous awards for Dr. Druker, including the John J. Kenney Award from The Leukemia and Lymphoma Society, the AACR-Richard, and many others.